Elanco

Elanco Animal Health Incorporated (NYSE: ELAN) is an American pharmaceutical company that develops and markets products for animal health. It was formerly a division of Eli Lilly and Company, becoming an independent, publicly traded company in 2019.

Overview:

Elanco's product portfolio encompasses a wide range of solutions for both companion animals and food animals. These include pharmaceuticals, vaccines, parasiticides, nutritional health products, and surgical tools. The company operates globally, with a significant presence in North America, Europe, and Asia-Pacific.

History:

Elanco was founded in 1954 as a division of Eli Lilly and Company. Initially focused on agricultural products, the division gradually shifted its focus to animal health. Over the decades, Elanco grew through internal research and development, as well as strategic acquisitions of other animal health companies. Key acquisitions include Novartis Animal Health (2015) and Bayer Animal Health (2020).

Products and Services:

Elanco's product categories are generally divided into:

• Companion Animal Health: This includes products for pets such as dogs, cats, and horses. These products focus on disease prevention, treatment of existing conditions, and improving the quality of life for pets.
• Food Animal Health: This encompasses products for livestock animals such as cattle, poultry, swine, and aquaculture. These products focus on improving animal health and productivity, promoting efficient food production, and ensuring food safety.

Corporate Social Responsibility:

Elanco emphasizes responsible animal health practices and sustainability. The company is involved in various initiatives aimed at improving animal welfare, reducing the environmental impact of livestock production, and promoting responsible use of antibiotics.

Headquarters:

Elanco's global headquarters are located in Greenfield, Indiana, USA.

Notable Acquisitions:

• Novartis Animal Health (2015)
• Bayer Animal Health (2020)